drugset / Trial / NCT00954122

Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

NCT00954122

Phase 4 Completed 35 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg Oral
Subject Quetiapine Small molecule 800 mg Oral

Indications